ANGO News and Press, AngioDynamics Inc. From 07/12/23

Fiscal Year 2023 Fourth Quarter Highlights Net sales of $91.1 million increased 4.7% compared to the prior-year quarter Med Tech net sales of $26.5 million increased 17.2% Med Device net sales of $64.6 million increased 0.3% Gross margin of 50.9% declined 2...

2023-07-09 03:09:09 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . For further details see: Wall Street Breakfast: The Week Ahead

2023-07-07 15:00:36 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...

2023-07-07 11:08:15 ET Next week marks the start of a crucial period as earnings season kicks off, with major companies from the financial, consumer, and technology sectors all set to release their quarterly financial results. Among the list of firms scheduled to announce their financia...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial re...

2023-06-14 16:42:19 ET Summary AngioDynamics and Merit Medical came together for a $100M transaction that will transfer ANGO's hemodialysis and BioSentry products to Merit. Merit is gaining more scale and adding specialty products in an already-important dialysis business, and thi...

2023-06-09 14:56:00 ET Shares of AngioDynamics (NASDAQ: ANGO) were up more than 8% Friday afternoon after rising as much as 9.1% on the news the medical technology company had sold some of its assets for $100 million. The stock is still down more than 21% so far this year. Angio...

2023-06-08 19:07:22 ET AngioDynamics ( NASDAQ: ANGO ) has completed the sale of its dialysis and BioSentry product lines to Merit Medical Systems for $100M in cash, which it plans to use to eliminate debt and for strategic purposes. The sale included AngioDynamics' portfolio of ...

Announces preliminary Fiscal Year 2023 net sales in the range of $338 million to $339 million AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatm...

2023-05-24 13:16:05 ET Summary Another mixed quarter in Q3 FY'22 for AngioDynamics, despite strengths in its international markets. Management revised guidance higher, but this may widen the operating loss as well, in my view. AngioVac sales aren't gaining traction, clamping t...